Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2012
05/03/2012US20120108638 Pyridin-4-yl derivatives
05/03/2012US20120108637 Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands
05/03/2012US20120108634 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
05/03/2012US20120108631 Sulfonamides for the Modulation of PKM2
05/03/2012US20120108627 Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
05/03/2012US20120108626 Multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical
05/03/2012US20120108618 Thia-triaza-indacenes
05/03/2012US20120108616 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
05/03/2012US20120108612 Inhibitors of bruton's tyrosine kinase
05/03/2012US20120108611 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
05/03/2012US20120108605 O-glcnac transferase inhibitors and uses thereof
05/03/2012US20120108603 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
05/03/2012US20120108590 Melt-extruded solid dispersions containing an apoptosis-inducing agent
05/03/2012US20120108589 Azabicyclo compound and salt thereof
05/03/2012US20120108588 Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives
05/03/2012US20120108587 Aza- and Diaza-Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof
05/03/2012US20120108584 2h or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
05/03/2012US20120108583 Tricyclic Compounds As mPGES-1 Inhibitors
05/03/2012US20120108574 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds
05/03/2012US20120108571 Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators
05/03/2012US20120108568 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
05/03/2012US20120108567 Thiazolyl-Dihydro-Indazoles
05/03/2012US20120108566 Nicotinamides as jak kinase modulators
05/03/2012US20120108563 Methods Of Treating Liposarcoma
05/03/2012US20120108562 Therapeutic compositions and methods
05/03/2012US20120108556 Methods and dosage forms for the treatment of human cancers
05/03/2012US20120108550 Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments
05/03/2012US20120108548 Molecular tweezers for the treatment of amyloid-related diseases
05/03/2012US20120108547 Inhibitors of tyrosine kinases and uses thereof
05/03/2012US20120108545 Trioxane Monomers and Dimers
05/03/2012US20120108534 Dihydrothienopyrimidines for the treatment of inflammatory Diseases
05/03/2012US20120108530 Enhanced Neoglycosides Through Neoglycosylation and Methods of Use Thereof
05/03/2012US20120108522 Hdac inhibitors and hormone targeted drugs for the treatment of cancer
05/03/2012US20120108521 Immunostimulatory compositions and uses thereof
05/03/2012US20120108520 Antimicrobial Compounds and Formulations
05/03/2012US20120108509 Artificial scab for use in an airway
05/03/2012US20120108494 Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof
05/03/2012US20120108422 Antifungal 1,2,4-triazolyl Derivatives
05/03/2012US20120107928 Antibody Inhibitors of GDF-8 and Uses Thereof
05/03/2012US20120107897 Double-stranded oligonucleotides
05/03/2012US20120107846 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
05/03/2012US20120107833 Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof
05/03/2012US20120107827 PSMCs As Modifiers of the RB Pathway and Methods of Use
05/03/2012US20120107417 Effective Antitumor Treatments
05/03/2012US20120107403 Bladder reconstruction
05/03/2012US20120107391 Therapy of platinum-resistant cancer
05/03/2012US20120107380 Methods of saponifying xanthophyll esters and isolating xanthophylls
05/03/2012US20120107365 Films and particles
05/03/2012US20120107364 Antibody having anti-cancer activity
05/03/2012US20120107347 Combination immunotherapy compositions against cancer and methods
05/03/2012US20120107343 Production of recombinant proteins in ciliates and uses thereof
05/03/2012US20120107337 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccines
05/03/2012US20120107333 Vangl1 peptides and vaccines including the same
05/03/2012US20120107332 Beta-Glucuronide-Linker Drug Conjugates
05/03/2012US20120107324 TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF
05/03/2012US20120107323 Kinase protein binding inhibitors
05/03/2012US20120107321 Antibodies And Epitopes Specific To Misfolded Prion Protein
05/03/2012US20120107319 Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1)
05/03/2012US20120107317 Use of cytoplasmic c-myc for regulating immune responses
05/03/2012US20120107312 Combinations for the Treatment of Diseases involving Cell Proliferation
05/03/2012US20120107311 Targeted identification of immunogenic peptides
05/03/2012US20120107309 Polymorphism in k-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation status
05/03/2012US20120107308 Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy
05/03/2012US20120107307 Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
05/03/2012US20120107306 Antibodies for epidermal growth factor receptor 3 (her3)
05/03/2012US20120107305 Combination Therapy
05/03/2012US20120107304 Combination therapy in treatment of oncological and fibrotic diseases
05/03/2012US20120107303 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
05/03/2012US20120107302 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
05/03/2012US20120107299 Phosphorylation-inhibiting agent or dephosphorylating agent for pten
05/03/2012US20120107298 Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction
05/03/2012US20120107294 Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umblical cord blood
05/03/2012US20120107293 Methods and compositions for the treatment of cancer
05/03/2012US20120107282 Neural stem cell composition capable of treating cancer and method of treatment
05/03/2012US20120107281 Compositions and methods for modifying cell surface glycans
05/03/2012US20120107275 Fused heterocyclic derivatives and methods of use
05/03/2012US20120107272 Synthetic methods and derivatives of triphosphate oligonucleotides
05/03/2012US20120107270 Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer
05/03/2012US20120107269 Thiophene derivatives
05/03/2012US20120107264 Nucleic acid delivery compounds
05/03/2012US20120107252 Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions
05/03/2012US20120107246 Methotrexate-modified nanoparticles and related methods
05/03/2012US20120107243 Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
05/03/2012US20120107237 Arg-gly-asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
05/03/2012US20120107235 Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof
05/03/2012US20120107234 Pan-HER Antibody Composition
05/03/2012US20120107233 Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
05/03/2012US20120107232 Kit for preparing a radiolabeled liposome and a method using the same
05/03/2012US20120107231 Metalloproteinase binding proteins
05/03/2012US20120107230 Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs
05/03/2012US20120104039 Medicament/Dosimeter Combination Packaging
05/03/2012DE102010049877A1 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate 7 - ((1,2,3) triazol-4-yl) pyrrolo (2,3) pyrazine
05/03/2012DE102010043318A1 Calciumcarbonat enthaltende Zusammensetzung Calcium carbonate-containing composition
05/03/2012CA2828238A1 Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib
05/03/2012CA2819230A1 Methods and compositions for assessing and treating cancer
05/03/2012CA2816570A1 Enhanced cancer treatment and monitoring using recombinant vectors
05/03/2012CA2816418A1 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
05/03/2012CA2816379A1 Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
05/03/2012CA2816358A1 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
05/03/2012CA2816291A1 Novel anti-dr5 antibody
1 ... 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 ... 2211